ChinaDrugStatus

Eplontersen sodium

依普隆特生钠
Brand: Wainua / 万诺维·Neurology / Rare Disease·Last verified 2026-11-20

Ligand-conjugated antisense therapy newly added to the 2026 Commercial Health Insurance Innovative Drug List (#24) for adult hereditary ATTR polyneuropathy.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Not Listed

Not included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).

Commercial Insurance List

Announced · Effective Jan 1, 2027
2026 List Entry
#24 · 万诺维
Validity Period
2027-01-01 to 2028-12-31
MAH / Authorized Entity
AstraZeneca AB · 阿斯利康(无锡)贸易有限公司
Listed Indication Scope
Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2027-01-01)Commercial List· Catalog published: Nov 14, 2026

    2026 Commercial List · Newly Added (#24)

    Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

    Chinese original: 本品适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。

    NHSA · PDF p.4Verified 2026-11-20

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

依普隆特生钠注射液dosage name(NHSA)
Wainuabrand en(WHO)
万诺维brand zh(NHSA)

Primary Sources for This Record